OXFORD - Physiomics plc (AIM: PYC), a UK-based company specializing in mathematical modelling and biostatistics for therapeutic development, has been awarded a new contract by Numab Therapeutics AG. The collaboration will utilize Physiomics’ expertise in Pharmacokinetic-Pharmacodynamic (PK/PD) modelling to refine the Target (NYSE:TGT) Candidate Profile (TCP) for a significant drug in development by Numab Therapeutics.
The project is set to be completed within six months and marks a continuation of the ongoing partnership between the two companies. Physiomics' role in this venture is to apply its modelling and simulation techniques to support the advancement of Numab Therapeutics' pipeline, enhancing the drug development process from early discovery through to development stages.
Dr Peter Sargent, CEO of Physiomics, expressed enthusiasm for the new contract, stating, "We are excited to build on our partnership with Numab Therapeutics AG and contribute to the advancement of this innovative therapy." He emphasized the importance of the collaboration in demonstrating Physiomics' growing capabilities to provide comprehensive support throughout the drug development lifecycle.
This announcement underscores the company's position in the field of personalized medicine and its contribution to streamlining the development of new therapies. The contract highlights Physiomics' commitment to addressing key challenges in drug development and its value-added approach across various therapeutic areas.
The financial terms of the contract were not disclosed. The information in this article is based on a press release statement from Physiomics plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.